诺华-话题@MedSci

#诺华#

235篇内容 | 5448人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1282693, encodeId=40161282693bd, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=重大打击！诺华急性心衰药物RLX030关键III期临床失败, objectType=article, longId=93796, objectId=066d93e9684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=066d93e9684, replyNumber=0, likeNumber=61, createdTime=2017-03-26, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=066d93e9684, moduleTitle=重大打击！诺华急性心衰药物RLX030关键III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=066d93e9684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282692, encodeId=33171282692e6, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华制药在韩国因不合规被惨罚，营销合规不能“抄小道”, objectType=article, longId=91514, objectId=675d9151465, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=675d9151465, replyNumber=0, likeNumber=71, createdTime=2017-03-14, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=675d9151465, moduleTitle=诺华制药在韩国因不合规被惨罚，营销合规不能“抄小道”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=675d9151465)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282691, encodeId=d42812826915d, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=2017，这10大重磅药物专利悬了！（礼来、吉利德、辉瑞、诺华……）, objectType=article, longId=89871, objectId=729f898e1b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=729f898e1b6, replyNumber=0, likeNumber=72, createdTime=2017-02-26, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=729f898e1b6, moduleTitle=2017，这10大重磅药物专利悬了！（礼来、吉利德、辉瑞、诺华……）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=729f898e1b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282690, encodeId=aae01282690dd, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华ceritinib获FDA优先审评，有望一线用于肺癌治疗, objectType=article, longId=89867, objectId=763d8986ec5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=763d8986ec5, replyNumber=0, likeNumber=84, createdTime=2017-02-26, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=763d8986ec5, moduleTitle=诺华ceritinib获FDA优先审评，有望一线用于肺癌治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=763d8986ec5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282689, encodeId=dd00128268952, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=Propeller Health和诺华公司合作，开发针对慢阻肺药物的智能传感器, objectType=article, longId=89275, objectId=ab13892e5f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab13892e5f6, replyNumber=0, likeNumber=50, createdTime=2017-02-19, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab13892e5f6, moduleTitle=Propeller Health和诺华公司合作，开发针对慢阻肺药物的智能传感器, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab13892e5f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282688, encodeId=6ac9128268892, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=市值935亿美元的BMS要卖？辉瑞罗氏诺华吉列德钱多到烧手……, objectType=article, longId=89245, objectId=f97c89245f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f97c89245f5, replyNumber=0, likeNumber=75, createdTime=2017-02-19, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f97c89245f5, moduleTitle=市值935亿美元的BMS要卖？辉瑞罗氏诺华吉列德钱多到烧手……, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f97c89245f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282687, encodeId=2ea2128268e99, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华药物依维莫司通过英国重新审查，作为二线药物治疗肾细胞癌, objectType=article, longId=87679, objectId=e73c8e67927, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e73c8e67927, replyNumber=0, likeNumber=83, createdTime=2017-01-19, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e73c8e67927, moduleTitle=诺华药物依维莫司通过英国重新审查，作为二线药物治疗肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e73c8e67927)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282686, encodeId=47861282686c5, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=喜讯！诺华重磅抗炎药Cosentyx获英国NICE批准治疗银屑病关节炎（PsA）, objectType=article, longId=86942, objectId=2a528694223, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a528694223, replyNumber=0, likeNumber=80, createdTime=2017-01-09, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a528694223, moduleTitle=喜讯！诺华重磅抗炎药Cosentyx获英国NICE批准治疗银屑病关节炎（PsA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a528694223)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282685, encodeId=fe6c1282685cb, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=赛诺菲和诺华在临床数据公开程度排名垫底！该改变态度了！, objectType=article, longId=82682, objectId=7b4b8268205, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b4b8268205, replyNumber=0, likeNumber=55, createdTime=2016-11-21, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b4b8268205, moduleTitle=赛诺菲和诺华在临床数据公开程度排名垫底！该改变态度了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b4b8268205)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282684, encodeId=1c9b128268488, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=瞪口呆！赛诺菲和诺华在临床数据公开程度排名垫底, objectType=article, longId=81957, objectId=12918195eef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12918195eef, replyNumber=0, likeNumber=49, createdTime=2016-11-09, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12918195eef, moduleTitle=瞪口呆！赛诺菲和诺华在临床数据公开程度排名垫底, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12918195eef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282683, encodeId=5d271282683ba, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华重磅抗炎药Cosentyx获英国NICE批准治疗强直性脊柱炎（AS）, objectType=article, longId=79466, objectId=39dee9466a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39dee9466a4, replyNumber=0, likeNumber=65, createdTime=2016-10-09, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39dee9466a4, moduleTitle=诺华重磅抗炎药Cosentyx获英国NICE批准治疗强直性脊柱炎（AS）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39dee9466a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282682, encodeId=9c201282682a9, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华药物Cosentyx持续治疗银屑病4年疗效仍佳, objectType=article, longId=79314, objectId=d3e6e93147b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3e6e93147b, replyNumber=0, likeNumber=57, createdTime=2016-10-07, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3e6e93147b, moduleTitle=诺华药物Cosentyx持续治疗银屑病4年疗效仍佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3e6e93147b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282681, encodeId=754112826817f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=重磅！FDA一次性批准诺华抗炎药Ilaris 3个新的适应症, objectType=article, longId=79021, objectId=679ce902173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=679ce902173, replyNumber=0, likeNumber=65, createdTime=2016-10-01, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=679ce902173, moduleTitle=重磅！FDA一次性批准诺华抗炎药Ilaris 3个新的适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=679ce902173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282680, encodeId=d9f5128268089, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保, objectType=article, longId=78707, objectId=88a4e870731, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88a4e870731, replyNumber=0, likeNumber=66, createdTime=2016-09-29, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88a4e870731, moduleTitle=重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88a4e870731)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282678, encodeId=a43e12826e87f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=EHMTIC 2016：诺华每月一次皮下注射药物AMG 334治疗慢性偏头痛显著降低每月偏头痛天数, objectType=article, longId=77929, objectId=90bfe792967, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90bfe792967, replyNumber=0, likeNumber=80, createdTime=2016-09-21, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90bfe792967, moduleTitle=EHMTIC 2016：诺华每月一次皮下注射药物AMG 334治疗慢性偏头痛显著降低每月偏头痛天数, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90bfe792967)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282679, encodeId=43d312826e9f1, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=CTRIMS 2016：诺华新药BAF312治疗继发进展型多发性硬化症（SPMS）关键III期显著降低残疾进展风险, objectType=article, longId=77933, objectId=e078e79331a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e078e79331a, replyNumber=0, likeNumber=58, createdTime=2016-09-21, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e078e79331a, moduleTitle=CTRIMS 2016：诺华新药BAF312治疗继发进展型多发性硬化症（SPMS）关键III期显著降低残疾进展风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e078e79331a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282677, encodeId=af8612826e715, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=观点：诺华战略收缩为中国CAR-T技术弯道超车提供机遇, objectType=article, longId=76664, objectId=c13ae666434, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c13ae666434, replyNumber=0, likeNumber=63, createdTime=2016-09-07, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c13ae666434, moduleTitle=观点：诺华战略收缩为中国CAR-T技术弯道超车提供机遇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c13ae666434)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282676, encodeId=bfea12826e6f0, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=第4个适应症！诺华抗癌药Arzerra获FDA批准治疗复发性慢性淋巴细胞白血病（CLL）, objectType=article, longId=76568, objectId=80e0e6568b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e0e6568b4, replyNumber=0, likeNumber=113, createdTime=2016-09-04, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e0e6568b4, moduleTitle=第4个适应症！诺华抗癌药Arzerra获FDA批准治疗复发性慢性淋巴细胞白血病（CLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e0e6568b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282675, encodeId=bbb712826e5cf, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华新一代免疫调节剂BAF312（siponimod）治疗继发进展型多发性硬化症（SPMS）III期临床获得成功, objectType=article, longId=75977, objectId=1959e5977e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1959e5977e7, replyNumber=0, likeNumber=72, createdTime=2016-08-28, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1959e5977e7, moduleTitle=诺华新一代免疫调节剂BAF312（siponimod）治疗继发进展型多发性硬化症（SPMS）III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1959e5977e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282674, encodeId=f60b12826e461, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）, objectType=article, longId=74627, objectId=2d0ae462726, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d0ae462726, replyNumber=0, likeNumber=78, createdTime=2016-08-08, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d0ae462726, moduleTitle=紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d0ae462726)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

诺华

2020-05-29发表于威斯康星

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

重大打击！诺华急性心衰药物RLX030关键III期临床失败

2017-03-26

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华制药在韩国因不合规被惨罚，营销合规不能“抄小道”

2017-03-14

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

2017，这10大重磅药物专利悬了！（礼来、吉利德、辉瑞、诺华……）

2017-02-26

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华ceritinib获FDA优先审评，有望一线用于肺癌治疗

2017-02-26

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

Propeller Health和诺华公司合作，开发针对慢阻肺药物的智能传感器

2017-02-19

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

市值935亿美元的BMS要卖？辉瑞罗氏诺华吉列德钱多到烧手……

2017-02-19

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华药物依维莫司通过英国重新审查，作为二线药物治疗肾细胞癌

2017-01-19

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

喜讯！诺华重磅抗炎药Cosentyx获英国NICE批准治疗银屑病关节炎（PsA）

2017-01-09

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

赛诺菲和诺华在临床数据公开程度排名垫底！该改变态度了！

2016-11-21

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

瞪口呆！赛诺菲和诺华在临床数据公开程度排名垫底

2016-11-09

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华重磅抗炎药Cosentyx获英国NICE批准治疗强直性脊柱炎（AS）

2016-10-09

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华药物Cosentyx持续治疗银屑病4年疗效仍佳

2016-10-07

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

重磅！FDA一次性批准诺华抗炎药Ilaris 3个新的适应症

2016-10-01

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保

2016-09-29

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

EHMTIC 2016：诺华每月一次皮下注射药物AMG 334治疗慢性偏头痛显著降低每月偏头痛天数

2016-09-21

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

CTRIMS 2016：诺华新药BAF312治疗继发进展型多发性硬化症（SPMS）关键III期显著降低残疾进展风险

2016-09-21

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

观点：诺华战略收缩为中国CAR-T技术弯道超车提供机遇

2016-09-07

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

第4个适应症！诺华抗癌药Arzerra获FDA批准治疗复发性慢性淋巴细胞白血病（CLL）

2016-09-04

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华新一代免疫调节剂BAF312（siponimod）治疗继发进展型多发性硬化症（SPMS）III期临床获得成功

2016-08-28

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）

2016-08-08

科室
- - 订阅+
  - 更多科室
工具
服务